173271-18-6

Upstream product

• 104769-15-5 [(2R,3S,5R)-3-hydroxy-5-[2-(2-methylpropanoylamino)-6-oxo-1H-purin-9-yl]tetrahydrofuran-2-yl]methyl benzoate 
• 961-07-9 2'-Deoxyguanosine 
• 68892-42-2 N-isobutyryl-2'-deoxyguanosine 
• 121513-00-6 [(2R,3R,5R)-2-(hydroxymethyl)-5-[2-(2-methylpropanoylamino)-6-oxo-1H-purin-9-yl]tetrahydrofuran-3-yl] benzoate 

Downstream Products

• 143526-98-1 N2-isobutyryl-9-(3-azido-5-O-benzoyl-2,3-dideoxy-β-D-erythro-pentofuranosyl)-guanine 
• 1085745-50-1 2-isobutyrylamino-9-(5'-O-benzoyl-3'-azido-2',3'-dideoxy-β-D-erythro-pentofuranosyl)-6-allylamino-9H-purine 

Relevant academic research and scientific papers

3'-AZIDO PURINE NUCLEOTIDE PRODRUGS FOR TREATMENT OF VIRAL INFECTIONS

The present invention is directed to compounds, compositions and methods for treating or preventing viral infections, in particular, HIV, and HBV, in human patients or other animal hosts. The compounds are 3'-azido-2',3'-dideoxy purine monophosphates, and pharmaceutically acceptable, salts, prodrugs, and other derivatives thereof. In particular, the compounds show potent antiviral activity against HIV-1 and HBV.

Synthesis and evaluation of 3′-azido-2′,3′-dideoxypurine nucleosides as inhibitors of human immunodeficiency virus

Based on the promising drug resistance profile and potent anti-HIV activity of β-d-3′-azido-2′,3′-dideoxyguanosine, a series of purine modified nucleosides were synthesized by a chemical transglycosylation reaction and evaluated for their antiviral activity, cytotoxicity, and intracellular metabolism. Among the synthesized compounds, several show potent and selective anti-HIV activity in primary lymphocytes.

AZIDO PURINE NUCLEOSIDES FOR TREATMENT OF VIRAL INFECTIONS

The present invention is directed to compounds, compositions and methods for treating or preventing viral infections, in particular, HIV, HBV, and HCV, in human patients or other animal hosts. The compounds are 3'-azido-2',3'-dideoxy purine nucleosides or